Monopar Therapeutics Inc. (NASDAQ:MNPR) Stock Rated “Moderate Buy” by Wall Street Analysts

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have earned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, six have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $122.00.

A number of equities research analysts have commented on MNPR shares. UBS Group set a $125.00 price target on Monopar Therapeutics in a report on Thursday, July 23rd. Morgan Stanley restated an “overweight” rating and set a $130.00 target price on shares of Monopar Therapeutics in a research report on Monday, August 17th. Zacks Research lowered shares of Monopar Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Monopar Therapeutics in a research note on Friday, July 17th. Finally, Barclays reaffirmed an “overweight” rating and issued a $145.00 price target (up from $128.00) on shares of Monopar Therapeutics in a research note on Friday, September 11th.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Raymond Anderson sold 3,142 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $111.77, for a total transaction of $351,181.34. Following the transaction, the director owned 23,751 shares of the company’s stock, valued at approximately $2,654,649.27. This trade represents a 11.68% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christopher Starr sold 8,400 shares of Monopar Therapeutics stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $78.50, for a total transaction of $659,400.00. Following the transaction, the director directly owned 5,173 shares in the company, valued at approximately $406,080.50. The trade was a 61.89% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 44,688 shares of company stock valued at $4,023,094 in the last 90 days. Insiders own 9.70% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the company. Bank of New York Mellon Corp acquired a new stake in Monopar Therapeutics in the second quarter valued at approximately $7,124,000. Bank of America Corp DE grew its holdings in Monopar Therapeutics by 838.2% in the first quarter. Bank of America Corp DE now owns 59,699 shares of the company’s stock worth $3,271,000 after purchasing an additional 53,336 shares during the last quarter. ADAR1 Capital Management LLC increased its position in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company’s stock worth $14,480,000 after purchasing an additional 30,370 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new position in shares of Monopar Therapeutics during the first quarter worth $250,000. Finally, Siren L.L.C. lifted its holdings in shares of Monopar Therapeutics by 27.2% during the 1st quarter. Siren L.L.C. now owns 270,118 shares of the company’s stock valued at $14,800,000 after purchasing an additional 57,820 shares during the last quarter. Institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Trading Down 1.8%

Shares of Monopar Therapeutics stock opened at $71.80 on Friday. The company’s fifty day simple moving average is $100.83 and its 200-day simple moving average is $84.21. Monopar Therapeutics has a 1-year low of $50.07 and a 1-year high of $124.82.

Monopar Therapeutics (NASDAQ:MNPR) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.64) by $0.02. As a group, research analysts predict that Monopar Therapeutics will post -2.98 EPS for the current year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments and diagnostic agents for cancer. The company’s research programs are designed to address serious diseases by using targeted approaches intended to improve the effectiveness and tolerability of oncology therapies.

Monopar’s portfolio has included camsirubicin, a next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The company has also developed MNPR-101, a therapeutic and imaging platform directed at the urokinase plasminogen activator receptor (uPAR), a protein associated with various aggressive cancers.